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Summary
 
The c-maf protooncogene is a T helper cell type 2 (Th2)-specific transcription factor that acti-
vates the interleukin (IL)-4 promoter in vitro. Although it has been postulated that c-maf di-
rects the Th2-specific expression of the IL-4 gene in vivo, direct evidence that c-maf functions
during the differentiation of normal, primary T cells is lacking. We now demonstrate that
overexpression of c-maf in vivo skews the Th immune response along a Th2 pathway, as evi-
denced by increased production of Th2 cytokines and the IL-4–dependent immunoglobulins,
IgG1 and IgE. The overproduction of IgGl and IgE in the CD4 promoter/c-maf transgenic
mice was IL-4 dependent since this was not observed in c-maf transgenic mice bred onto an
IL-4–deficient background. Ectopic expression of c-maf in mature Th1 cells did not confer on
them the ability to produce IL-4, but did decrease the production of IFN-
 
g
 
. The attenuation
of Th1 differentiation by c-maf overexpression occurred by a mechanism that was independent
of IL-4 and other Th2 cytokines, and could be overcome by IL-12. These studies demonstrate
that c-maf promotes Th2 differentiation by IL-4–dependent mechanisms and attenuates Th1
differentiation by Th2 cytokine-independent mechanisms.
Key words: interleukin 4 • T helper cells • c-maf • transcription factor
 
T
 
he cytokine IL-4 is known to regulate a broad spectrum
of biologic activities including activation, growth, and
differentiation of T and B lymphocytes, macrophages, and
cells of the inflammatory and hematopoietic systems (1–4).
The receptor for IL-4 is expressed on most cells of hematopoi-
etic lineage and, when occupied with its ligand, induces a pro-
gram of gene activation mediated primarily by the Stat6 and
insulin receptor substrate (IRS)-2 transcription factors (5–7).
One of the most important consequences of IL-4 pro-
duction is the generation of a selected subset of CD4 T
helper cells termed Th2 (8, 9). These cells secrete a panoply
of cytokines, including IL-4 itself, IL-5, IL-10, and IL-13,
that are critical in the allergic response and in mounting an
effective immune response to parasites and nematodes. Fur-
thermore, the relative ratio of IL-4–producing Th2 cells to
the opposing CD4 IFN-
 
g
 
–producing Th1 subset has dra-
matic consequences for the immune response to diverse
antigens, including pathogens, autoantigens, tumor anti-
gens, and allergens. For example, in the nonobese diabetic
mouse, a mouse model of the human disease insulin-depen-
dent diabetes mellitus, Th1 cells are pathogenic (10, 11).
Enhancing the formation of Th2 cells at the expense of
Th1 cells, in such mice, either through the direct adminis-
tration of recombinant IL-4 or through altering T cell/co-
stimulatory molecule interactions, results in disease amelio-
ration (12, 13). Furthermore, IL-4 is necessary to initiate
and sustain in vivo IgE responses as demonstrated by the
failure of IL-4–deficient animals to mount IgE responses to
infection (14–16).
IL-4 is a highly tissue-specific gene whose expression is
limited to Th2 cells, a small population of CD4
 
1
 
NK1.1
 
1
 
 T
cells, basophils, and mast cells (17–19). Resting T cells do
not transcribe IL-4 until activated through the TcR or
with pharmacologic agents such as PMA and Ca
 
2
 
1
 
 iono-
phores. The minimal IL-4 promoter sufficient to confer
Th2 specificity and inducibility has been identified and
characterized (20). It contains functionally critical binding
sites for a family of transcription factors called nuclear factor
of activated T cells (NFAT),
 
1
 
 and for activator protein
(AP)–1 family members. However, none of these factors
can explain the Th2 cell specificity of the IL-4 gene (21).
 
1
 
Abbreviations used in this paper:
 
 NFAT, nuclear factor of activated T cells;
RT, reverse transcription.
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Recently, we have shown that the protooncogene c-maf is
expressed in Th2 but not in Th1 clones and is induced dur-
ing the differentiation of normal Thp along a Th2 but not a
Th1 lineage. c-maf is a basic region/leucine zipper tran-
scription factor that belongs to the subfamily of AP-1/
CREB/ATF proteins and, like them, forms homo- and
heterodimers (22). Homodimers of c-maf can bind to a se-
quence adjacent to a Th2-specific footprint and immedi-
ately downstream of an NFAT site in the proximal IL-4
promoter. Ectopic expression of c-maf in Th1 cells, B cells,
and HepG2 cells can transactivate an exogenous IL-4 pro-
moter. Furthermore, c-maf, in synergy with NFATp, can
initiate endogenous IL-4 production in B cells. These ob-
servations led us to conclude that c-maf directs tissue-spe-
cific IL-4 expression in Th2 cells (21).
Although we have shown that c-maf is a potent transac-
tivator of the IL-4 gene in vitro, the function of c-maf dur-
ing Th cell differentiation in vivo was unknown. Further-
more, it was possible that c-maf may regulate genes in
addition to IL-4. To address these questions, we have gen-
erated transgenic mice overexpressing c-maf in both imma-
ture and mature T cells. Here we report that c-maf trans-
genic mice have an increased Th2 immune response in
vivo and in vitro that can be ablated by backcrossing onto
an IL-4–deficient background. In addition, c-maf, in the
absence of IL-12, attenuates the differentiation of Th1 cells
by a mechanism that is independent of Th2 cytokines.
Taken together, these observations provide strong evidence
for a critical role of c-maf in mediating Th2 cell differenti-
ation through both IL-4–dependent and –independent
mechanisms.
 
Materials and Methods
 
Generation of c-maf Transgenic Mice. 
 
A 4-kb full-length cDNA
encoding the murine c-maf gene was cloned into the SalI site of
the transgenic expression vector, p37.1 (gift of Dr. D. Littman,
New York University Medical School, New York, NY), which
contains the CD4 promoter/enhancer and the first intron with-
out the silencer element (23). c-maf transgenic mice were identi-
fied by digesting genomic DNA with SalI, followed by Southern
analysis using a c-maf–specific probe from the 3
 
9
 
UTR. Subsequent
screening of c-maf transgenic mice was carried out by genomic
PCR using the following primers: c-maf primer: 5
 
9
 
-TGTTGTG-
GTGCAGAACTGGAT-3
 
9
 
. p37-1 primer; 5
 
9
 
-GTTTCAGGT-
TCAGGGGGAGGT-3
 
9
 
.
 
Northern Analysis and Reverse Transcription PCR. 
 
Total RNA
was prepared from thymi or spleens of wild-type or c-maf trans-
genic mice using the Trizol reagent according to the manufac-
turer’s instructions (GIBCO BRL, Gaithersburg, MD). 10 
 
m
 
g of
each RNA sample was fractionated on 1.2% agarose gel, trans-
ferred to a Hybond membrane, and subsequently hybridized with
specific probes in QuickHyb buffer. The probe for the c-maf
transgene contains part of the first exon of the CD4 gene and the
first 347 bp of the c-maf cDNA. Reverse transcription (RT)–
PCR was performed by using the Access RT-PCR kit (Promega,
Madison, WI). The sequence of the primers used to amplify the
spliced c-maf transgenic mRNA were the CD4 upstream primer,
5
 
9
 
-ACACACACCTGTGCAAGAAGC-3
 
9
 
, and 5
 
9
 
-CTCTCCT-
CTTCTGCCTGGCTCTTATGGTTA-3
 
9
 
. Primers used to am-
plify CD4 were the CD4 upstream primer and the CD4 down-
stream primer 5
 
9
 
-TCCTCTGGTCAGAGAACTTCC-3
 
9
 
. The
c-maf–specific internal primer used for southern analysis was 5
 
9
 
-
AGCCGAGAGCAAAAGGGTTGG-3
 
9
 
.
 
Purification of Naive CD4
 
1
 
 
 
T Cells. 
 
Lymph node cells were
harvested, stained with FITC-conjugated anti–CD4 antibody and
PE-conjugated Mel-14 antibody, resuspended in unsupplemented
RPMI at 10
 
6 
 
cells per ml, and subjected to sorting by a MO FLO
(Cytomation, Fort Collins, CO) cell sorter. The CD4
 
1
 
 and Mel-
14 high cells were collected as naive cells and used in in vitro dif-
ferentiation assays.
 
In Vitro Differentiation of Th Cells. 
 
Spleen cells were harvested
and stimulated in vitro with plate-bound anti–CD3 mAb (2C11)
at 1 
 
m
 
g/ml alone and/or anti–CD28 (1 
 
m
 
g/ml) for naive T cells
(nonskewing conditions), or with anti–IL-12 mAb (5C3) at 20
 
m
 
g/ml (Th2 skewing conditions), anti–IL-4 mAb (11B11) at 5
 
m
 
g/ml (Th1 skewing conditions), anti–IL-10 mAb (R & D Sys-
tems, Inc., Minneapolis, MN) at 0.2 
 
m
 
g/ml, or anti–IL-13 mAb
(R & D Systems, Inc.) at 0.2 
 
m
 
g/ml. 24 h poststimulation, IL-2 at
50 U/ml was added to all cultures. In addition, IL-4 at 500 U/ml
or IL-12 at 50 U/ml was added into Th2 or Th1 cultures, respec-
tively. 7 d after stimulation, cells were harvested, washed thor-
oughly, and restimulated with plate-bound anti–CD3. 24 h after
restimulation, supernatants were harvested and subjected to
ELISA. Under these conditions, we find that 
 
z
 
80% of the popu-
lation at the end of the secondary stimulation are CD4
 
1
 
 
 
T cells.
 
Intracellular Cytokine Staining. 
 
Cells were first incubated with
2 
 
m
 
M Monesin in complete medium for 5–6 h, and subsequently
fixed with 4% paraformaldehyde and permeabilized with Sapo-
nin. The fixed and permeabilized cells were incubated with PE-
or FITC-conjugated anticytokine antibodies (PharMingen, San
Diego, CA) or control antibodies for 30 min on ice, washed with
0.1% BSA in PBS, and subjected to flow cytometric analysis on a
FACS
 
Ò
 
 (Becton Dickinson & Co., Mountain View, CA), and an-
alyzed with Cellquest software.
 
Results
 
Generation of c-maf Transgenic Mice. 
 
To study the func-
tion of c-maf in vivo, we have generated mouse strains
overexpressing c-maf in immature and mature T cells. A
full-length cDNA encoding murine c-maf was inserted
into a transgenic cassette that contained the CD4 pro-
moter/enhancer and first intron without the silencer ele-
ment, shown to be expressed in all T cells (23) (Fig. 1 
 
A
 
).
The resulting c-maf transgenic construct was injected into
C57BL/6 blastocysts. From twenty independent offspring
analyzed, six founders that had incorporated the c-maf
transgene as determined by genomic Southern analysis
were identified. Three of the 6 founder lines, all low copy
number transgenics, transmitted the transgene to offspring,
and all three lines displayed the phenotype which will be
described below. Line 6666 expressed moderately high lev-
els of transgenic c-maf mRNA of the expected size in thy-
mus but only low levels in spleen (Fig. 1 
 
B
 
). Line 6272 ex-
pressed very low levels of transgenic c-maf which could
only be detected by RT-PCR in both thymus and spleen
(Fig. 1 
 
C
 
). The third line, 6669, was lost before a careful
documentation of its level of expression of the c-maf trans-
gene, but also exhibited the phenotype described below. 
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The transgenic mice were born healthy and survived nor-
mally up to 12 months. It is curious that none of several
high copy c-maf transgenic founder lines successfully trans-
mitted the transgene to offspring (Ho, I-C., unpublished
observations). Although the reason for this is unknown, it
is reminiscent of unsuccessful attempts to produce IL-4
transgenic mice using a very potent Ig promoter that failed
secondary to neonatal lethality until an attenuated pro-
moter was used (24).
 
c-maf Transgenic Mice Display a Th2 Phenotype. 
 
Previously,
we have shown that c-maf is a Th2 cell-specific transcrip-
tion factor that can by itself transactivate both an exoge-
nous IL-4 promoter (21) and the endogenous IL-4 gene in
T cells (our unpublished data) and that, together with
NFAT and NIP45 proteins, can activate the endogenous
IL-4 promoter in non-T cells. Given these data, it was our
expectation that provision of c-maf to normal Thp cells by
transgenesis would allow them to transcribe the IL-4 gene.
Such mice might overproduce IL-4 and other Th2 cyto-
kines and have increased levels of the IL-4–dependent im-
munoglobulins IgG1 and IgE. We examined sera from un-
immunized C57Bl/6 wild-type mice and from the three
lines of c-maf transgenic mice by ELISA to quantitate the
basal levels of IL-4 and immunoglobulin isotypes. Al-
though levels of serum IL-4 were below detection in both
wild-type and c-maf transgenic mice, all three c-maf trans-
genic lines had significantly higher levels of IgE and IgG1
(5–10-fold) than did wild-type littermates (Fig. 2). In con-
trast, there was no difference in levels of IFN-
 
g
 
–dependent
IgG2a between wild-type and transgenic mice (Fig. 2).
In addition to controlling the isotype switch to IgG1 and
IgE, IL-4 is essential for promoting the differentiation of
Th2 cells. To test whether Th cells derived from c-maf
transgenic mice preferentially develop along a Th2 lineage
upon TcR-mediated stimulation, an in vitro differentiation
assay was performed. Splenocytes obtained from both wild-
type and c-maf transgenic mice were stimulated in vitro
with plate-bound anti–CD3 for 7 d, washed thoroughly,
and restimulated with anti–CD3. 24 h after the secondary
stimulation, supernatant was harvested and cytokine levels
were quantitated by ELISA. Under these “nonskewing”
conditions, splenocytes derived from wild-type C57BL/6
became “classical” Th1 cells secreting high levels of IFN-
 
g
 
and very low, if not undetectable, levels of the Th2 cyto-
kines, IL-4, IL-5, and IL-10 (Fig. 3 and Table 1). In con-
trast, under the same conditions, splenocytes derived from
the c-maf transgenic line 6666 differentiated into classical
Th2 cells producing high levels of Th2 cytokines and sig-
nificantly lower levels of IFN-
 
g
 
 than wild type. A clear
gene dosage effect of the c-maf transgene was apparent
since splenocytes derived from the lower expresser c-maf
transgenic line 6272 matured into Th1-like cells secreting
Figure 1. Generation of c-maf transgenic mice. (A) Schematic diagram
of the c-maf transgenic construct. Filled arrows represent primers used to
screen c-maf transgenic mice. Open arrows represent primers used for
RT-PCR. (B) Northern analysis of c-maf transgenic mice. Total RNA
prepared from thymi or spleens of c-maf transgenic or wild-type mice was
probed with a c-maf–specific probe. The same blot was also hybridized
with a g-actin–specific probe to quantify loading of RNA. (C) RT-PCR
analysis of c-maf transgenic mice. Total RNA prepared from thymi or
spleen of line 6272 or from wild-type mice was used as template in RT-
PCR analysis using the primers described above. The 409-bp RT-PCR
product, containing the spliced c-maf transgenic transcript, was further
confirmed by Southern blot analysis using an internal oligonucleotide as
probe. A 266-bp fragment of the spliced CD4 transcript was also ampli-
fied by RT-PCR as a control. Sequences of all the primers used are de-
scribed in Materials and Methods.
Figure 2. ELISA analysis of serum
immunoglobulin. Sera obtained from
unimmunized wild-type (WT), three
c-maf transgenic (6666, 6669, 6272),
c-maf transgenic/IL-4–deficient (maf-
TGxIL-4-/-) and IL-4–deficient (IL-
4-/-) mice were analyzed by ELISA for
IgE, IgG1, and IgG2a. 
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high levels of IFN-
 
g
 
 and very low levels of IL-4 and IL-5.
Interestingly, 6272 splenocytes did produce high levels of
IL-10 comparable with that of wild-type Th2 cells gener-
ated under Th2-skewing conditions.
 
The Th2 Phenotype of c-maf Transgenic Mice Is IL-4 Depen-
dent. 
 
Since the basal serum level of IL-4 in both wild-
type and c-maf transgenic mice was below the detectable
range, it was important to establish that the Th2 phenotype
of these mice was due to overproduction of IL-4. IL-4–
deficient mice do not mount Th2-type responses and have
impaired production of IgG1 and IgE (14–16). We there-
fore introduced the c-maf transgene (line 6666) onto an IL-
4
 
2
 
/
 
2
 
 
 
background, and these doubly transgenic mice are
henceforward called mafTG
 
3
 
IL-4
 
2
 
/
 
2
 
 
 
mice. As shown in
Fig. 2, in contrast to c-maf transgenic mice, mafTG
 
3
 
IL-
4
 
2
 
/
 
2
 
 mice had normal levels of serum IgE and IgG1. Fur-
thermore, similar to splenocytes derived from wild-type
mice, splenocytes derived from mafTG
 
3
 
IL-4
 
2
 
/
 
2
 
 mice dif-
ferentiated into Th1 cells under nonskewing conditions
(Fig. 4). Similar results were obtained when splenocytes de-
rived from line 6666 were stimulated in vitro in the pres-
ence of anti–IL-4 antibody (Fig. 5 
 
A
 
). These results con-
firm that the Th2 phenotype of the c-maf transgenic mice
is dependent on IL-4 and also demonstrate that Th1 cells
can be generated normally in vitro from c-maf transgenic
mice in the absence of IL-4.
 
Overexpression of c-maf Alone Is Not Sufficient to Induce the
Production of IL-4 by Normal Th1 Cells. 
 
Previously, we have
demonstrated that ectopic expression of c-maf in mature,
effector Th1 clones allows them to transactivate an exoge-
nous IL-4 promoter in in vitro assays. Given the low trans-
fection efficiency of these clones, we were not able to test
whether ectopic expression of c-maf permits endogenous
production of IL-4 by established Th1 cells. The overpro-
duction of IL-4 in the c-maf transgenic line could be as-
cribed to enhanced skewing of Thp cells towards a Th2 path-
way, to increased production of IL-4 by mature Th2 cells
and/or to production of IL-4 by mature effector Th1
cells. To distinguish among these possibilities, Th1 cells
were generated from c-maf transgenic mice, hence called
transgenic Th1 cells, by using an in vitro differentiation
protocol under Th1-skewing conditions. We could not de-
tect any IL-4 production by ELISA by transgenic Th1 cells
under these conditions (data not shown). However, it was
possible that, on a single cell basis, a small percentage of the
Figure 3. Th cells of c-maf
transgenic mice are skewed to-
ward a Th2 pathway upon stim-
ulation. Splenocytes derived
from wild-type (WT) and two
c-maf transgenic (6666, 6272)
mice were differentiated in vitro
under nonskewing conditions
according to the protocol de-
scribed in Materials and Meth-
ods. Supernatants were harvested
24 h after the secondary stimula-
tion and cytokine profile quanti-
tated by ELISA. As controls,
wild-type splenocytes were also
differentiated in vitro under
Th1-skewing (WT Th1) or Th2-
skewing (WT Th2) conditions.
Figure 4. The Th2-skewing
effect is dependent on IL-4.
Splenocytes derived from wild-
type (WT) and c-maf transgenic/
IL-4–deficient (mafTGxIL-4-/-)
mice were differentiated under
nonskewing conditions in vitro
and the cytokine profiles quanti-
tated by ELISA as described in
Fig. 3. The transgenic line used
is line 6666.
 
Table 1.
 
Summary of In Vitro Differentiation of Th Cells
 
IL-4 IL-15 IL-10 IFN-
 
g
 
Exp 1
WT Th1 (%) 5 1 8 100
WT Th2 (%) 100 100 100 10
WT (%) 5 11 12 86
6272 (%) 8 19 86 51
6666 (%) 113 68 144 38
Exp 2
WT Th1 (%) 0 0 0 100
WT Th2 (%) 100 100 100 80
WT (%) 0 0 0 103
6272 (%) 0 0 12 121
6666 (%) 14 88 99 82
Exp 3
WT Th1 (%) 23 36 11 100
WT Th2 (%) 100 100 100 28
WT (%) 15 39 9 119
6272 (%) 28 40 33 63
6666 (%) 214 114 93 51
Three independent experiments using in vitro differentiation of Th
cells were performed as described in Fig. 3. The levels of IFN-
 
g
 
 ob-
tained from wild-type Th1 (
 
WT Th1
 
) cells and the levels of Th2 cyto-
kines (IL-4, IL-5, and IL-10) obtained from wild-type Th2 (
 
WT Th2
 
)
cells were arbitrarily normalized to 100%. The actual concentration of
cytokines from experiment 1 is shown in Fig. 3. 
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transgenic Th1 cells might be producing both IFN-
 
g
 
 and
IL-4. To test this hypothesis, intracellular cytokine staining
was used to evaluate the production of IFN-
 
g
 
 and IL-4 by
transgenic Th1 cells. Although a small number of mature
transgenic Th cells stained positive for IL-4, no IL-4/IFN-
 
g
 
double positive cells were detected (Fig. 5 
 
C
 
). One possible
explanation is that the level of c-maf in transgenic Th1 cells
was below the physiological level required for transactiva-
tion of the endogenous IL-4 gene. To rule out this pos-
sibility, levels of c-maf mRNA were assessed by Northern
analysis. As shown in Fig. 5 
 
B
 
, the level of c-maf transcripts
in transgenic Th1 cells was comparable to that of wild-type
Th2 cells. We conclude that overexpression of c-maf
alone, to a level comparable to that of wild-type Th2 cells,
is not sufficient to transactivate the endogenous IL-4 pro-
moter in Th1 cells.
 
c-maf, Independent of IL-4, Attenuates the Th1 Pathway in
the Absence of IL-12. 
 
We have demonstrated that the Th2
phenotype of c-maf transgenic mice is IL-4 dependent, and
that Th1 cells can be generated normally in vitro from
these mice in the presence of exogenous IL-12 (Fig. 3 and
Table 1). However, we noted that the amount of IFN-
 
g
 
produced by c-maf transgenic Th cells under nonskewed
conditions was less than that of wild-type Th cells. The
impaired production of IFN-
 
g
 
 was not secondary to over-
production of IL-4 since mature nonskewed mafTG
 
3
 
IL-
4
 
2
 
/
 
2
 
 Th cells also produced z50% less IFN-g than was pro-
duced by mature IL-42/2 Th cells (Fig. 4). This difference
between double transgenic and IL-42/2 Th cells was also
reflected in the smaller number of IFN-g–positive cells de-
tected by intracellular staining of the nonskewed popula-
tions (data not shown). Thus, ectopic expression of c-maf
in the absence of IL-4 resulted in impaired IFN-g produc-
tion. One possible explanation for this result was that un-
fractionated mafTG3IL-42/2  splenocytes might contain
increased numbers of Th2 memory cells that had been gen-
erated in vivo. Another potential explanation was that
mafTG3IL-42/2  antigen presenting cells, such as mac-
rophages and dendritic cells, might produce less IL-12,
which is required for Th1 differentiation. Alternatively,
overexpression of c-maf in Th cells might transactivate a
yet-to-be-defined target gene, other than IL-4, able to at-
tenuate the development of Th1 cells.
To distinguish among these hypotheses, naive Thp cells
derived from IL-42/2 and maf TG3IL-42/2 mice were
purified by cell sorting and stimulated with plate-bound
anti–CD3 and anti–CD28 in vitro in the presence or ab-
sence of recombinant IL-12. As shown in Fig. 6 A, naive
IL-42/2 Thp cells differentiated into Th1 cells producing
high levels of IFN-g in the absence of recombinant IL-12.
Addition of recombinant IL-12 did not further enhance the
production of IFN-g (data not shown). In contrast, naive
c-mafTG3IL-42/2 Thp cells that had been differentiated
in the absence of IL-12 produced significantly lower levels
of IFN-g (z30% of control) than that produced by IL-42/2
mice. Of interest, no such difference was noted when IL-12
was added into the culture (Fig. 6 B). Consistent with the
lower levels of IFN-g, differentiated c-mafTG3IL-42/2
Th cells produced significantly higher levels of IL-10 than
did differentiated IL-42/2 Th cells (Fig. 6 A). This result
strongly argues against a role for Th2 memory cells or IL-12
production as responsible for the impaired production of
IFN-g. Rather, it argues for the presence of c-maf target
genes, other than IL-4, in Th cells that can attenuate the
Th1 pathway via an IL-4–independent mechanism.
However, it has been demonstrated that other Th2 cy-
Figure 5. c-maf alone is insufficient
to transactivate the endogenous IL-4
promoter in mature Th1 cells. (A) Lev-
els of IFN-g produced by mature Th1
cells, derived from splenocytes of wild-
type (WT) and c-maf transgenic (6666)
mice, generated by in vitro differentia-
tion under Th1-skewing conditions. (B)
Northern analysis of c-maf expression in
wild-type Th1 (WT Th1), c-maf trans-
genic Th1 (6666 Th1), and wild-type
Th2 (WT Th2) cells generated by in
vitro differentiation. (C) Intracellular
cytokine staining of wild-type (WT) or
c-maf transgenic (6666) Th1 cells using
FITC-conjugated anti–IFN-g and PE-
conjugated anti–IL-4 antibodies. FITC-
and PE-conjugated isotype control anti-
bodies were also used to determine
background staining.1864 Th2 Phenotype of c-maf Transgenic Mice
tokines, such as IL-13 and IL-10, can also promote the dif-
ferentiation of Th2 cells (25–27). Thus, yet another possi-
ble explanation was that the c-maf transgene induced the
production of Th2 cytokine genes other than IL-4 that at-
tenuated the Th1 pathway. To test this hypothesis, in vitro
differentiation experiments similar to those described above
were performed in the absence or presence of anti–IL-13
or anti–IL-10 antibodies. As shown in Fig. 6 B, addition of
anti–IL-13 or anti–IL-10 could not restore the ability of
mafTG3IL-42/2 Th cell to produce normal levels of IFN-g.
Taken together, these experiments demonstrate that, in the
absence of IL-4, c-maf is able to attenuate the Th1 pathway
via a Th2-cytokine–independent mechanism.
Discussion
Previously, we have demonstrated that the c-maf proto-
oncogene, a Th2-specific transcription factor, can transacti-
vate both exogenous and endogenous IL-4 promoters in
Th clones and in lymphoid tumor cells. In this report, we
now provide evidence that provision of c-maf to normal T
cells drives them to increased production of IL-4. Trans-
genic mice that overexpress c-maf in normal T cells dis-
played an IL-4–dependent enhancement of Th2 cell differ-
entiation as manifested by increased levels of IgG1 and IgE
and preferential development of Th2 cells in in vitro differ-
entiation assays. Interestingly, ectopic expression of c-maf
in mature Th1 cells did not confer on them the ability to
produce IL-4, but did attenuate the production of IFN-g.
These results establish that c-maf is a potent transactivator
of the IL-4 gene both in vivo and in vitro. In addition,
these data suggest the presence of additional c-maf target
gene(s) in T cells that function to attenuate the Th1 path-
way by a mechanism that is Th2-cytokine independent.
Although c-maf transgenic mice have significantly higher
basal levels of serum IgE and IgG1 than nontransgenic lit-
termates, these levels are considerably lower than those
found in mice transgenic for the IL-4 gene itself (24). This
difference is likely explained by an IL-4 gene dosage effect.
In c-maf transgenic mice, levels of IgE and IgG1 are deter-
mined by the amount of endogenous IL-4. Since the c-maf
founder lines were low copy number and low expresser
transgenics, levels of endogenous IL-4 were unlikely to be
greatly elevated; indeed, we did not detect serum IL-4 by
ELISA. In contrast, much higher levels of IgE and IgG1
can be expected in IL-4 transgenic mice that carry multiple
copies of an exogenous IL-4 gene driven by a fairly strong
Ig promoter. The differences in IL-4 levels may also ex-
plain the lack of allergic blepharitis in c-maf compared with
IL-4–transgenic mice. In addition to increased IgE and
IgG1 levels, c-maf transgenic mice, in particular line 6666,
also displayed preferential Th2 responses upon stimulation
in vitro. This effect was very noticeable since T cells from
the C57BL/6 background into which the transgene was in-
troduced are strongly directed along a Th1 pathway. Line
6272, expressing very low levels of the c-maf transgene,
only detectable by RT-PCR, did not have elevated IL-4
production in vitro. Nevertheless, serum levels of IgE and
IgG1 were elevated, suggesting that the isotype switch is a
very sensitive biological marker of functional IL-4. The
phenotype of this line further suggests that a very modest
increase in levels of c-maf can effect a Th2 shift in vivo. It
will be of interest to determine whether c-maf transgenic
mice are more resistant to the development of autoimmune
diseases using models such as the NOD and MRL/lpr
strains.
What is the source of the increased IL-4 produced by
c-maf transgenic T cells? The CD4 promoter/enhancer
drives expression of c-maf in naive Thp cells as well as in
mature Th1 and Th2 cells. The elevated IL-4 production
observed could be secondary to maf-induced preferential
skewing of naive Thp cells along a Th2 pathway, and/or to
overproduction of IL-4 by mature Th2 and Th1 cells. Our
data demonstrate that preferential skewing of Thp cells and
increased production of IL-4 by mature Th2 cells is the
likely explanation, as discussed below.
c-maf is a potent transactivator of the IL-4 promoter-
reporter construct in mature effector Th1 clones, and its
provision is sufficient to allow endogenous IL-4 production
in the Jurkat human Th1 cell line (our unpublished obser-
vations). Nevertheless, ectopic expression of c-maf in our
transgenic lines, in normal, mature Th1 cells, to a level
comparable to that present in mature wild-type Th2 cells,
did not permit them to express IL-4. This result implies ei-
ther that positive transacting factors in addition to c-maf are
required to drive IL-4 expression in normal Th1 cells, or
that an active repressor mechanism exists in Th1 cells in
vivo. The first possibility is consistent with the identifica-
tion of two other Th2-specific transcriptional factors,
GATA-3 and NF-IL-6 (C/EBPb) (28–30). Both factors
have been demonstrated to transactivate the IL-4 promoter
in vivo or in vitro. It is intriguing in this regard that provi-
sion of c-maf alone to Jurkat cells allows them to produce
endogenous IL-4 since Jurkat cells do in fact express
GATA-3 (31). A requirement for the presence of more
Figure 6. c-maf is able to at-
tenuate the Th1 pathway by IL-
4–independent mechanism(s).
Levels of IFN-g and IL-10 pro-
duced by naive Th cells of c-maf
transgenic/IL-4–deficient (maf-
TGx IL-4-/-) and IL-4–deficient
(IL-4-/-) mice, subjected to in
vitro differentiation under non-
skewing conditions in the absence
(A) or presence (B) of anti–IL-13,
anti–IL-10, or IL–12. The level
of IFN-g produced by mature
IL-42/2 Th cells in B was arbi-
trarily normalized to 100%.1865 Ho et al.
than one Th2-specific factor to allow IL-4 production by
Th1 cells can be best tested by generating c-maf/GATA-3
or c-maf/NF-IL6 double transgenic mice. Alternatively,
there may be active inhibitory mechanisms that repress the
IL-4 promoter in Th1 cells. This hypothesis is consistent
with the recent identification of a dominant silencer ele-
ment that actively suppresses the activity of the IL-4 pro-
moter in Th1 cells, but it does not fit well with our own
observation that transient Th1–Th2 heterokaryons produce
both IL-2 and IL-4 (21, 32).
Overexpression of c-maf resulted in impaired IFN-g
production, an effect that was Th2-cytokine independent,
and could be overcome by the addition of exogenous IL-12.
It is possible that c-maf directly represses the transcription
of the IFN-g gene, although this possibility cannot be
tested since the Th1-specific regulatory regions of the IFN-g
gene have yet to be identified. A direct repressor mecha-
nism would be consistent with recent reports demonstrat-
ing that ectopic expression of maf family members can re-
press gene expression. Thus, c-maf/c-Myb dimers suppress
the expression of the myeloid-specific gene, CD13/APN,
and a mafB/Ets complex inhibits erythroid differentiation
(33–35). The physiologic import of these studies, however,
is unclear since they involve inappropriate expression of
maf proteins. We would hypothesize that if c-maf is a bio-
logically relevant repressor of IFN-g, it must be acting very
early in Th cell differentiation, specifically at the Thp stage
since c-maf is expressed at very low levels in Thp cells (our
unpublished observations). This is consistent with our data
that the repressive effect of c-maf on IFN-g production
was overridden by the addition of rIL-12. Thus, mature ef-
fector transgenic Th1 cells produced normal levels of IFN-g.
Therefore, if c-maf indeed directly represses IFN-g gene
transcription, it only does so in Thp and not in mature Th1
cells. Another explanation for the Th1-attenuating, IL-4–
independent effect of c-maf is that it controls the expres-
sion of other genes in Thp cells that repress the Th1 pro-
gram. These genes are not the Th2 cytokines IL-5, IL-10,
and IL-13 since we demonstrated no effect of blocking
these cytokines on IFN-g production. Although IFN-g it-
self may be one such c-maf target gene, there may well be
others. The availability of lymphoid tissue from c-maf
overexpresser transgenic and c-maf–deficient strains should
allow the isolation of such genes.
In conclusion, we have shown that overexpression of
c-maf in vivo is able to skew the Th immune response to a
Th2 type via both IL-4–dependent and –independent
mechanisms. The overproduction of IL-4 is consistent with
our previous report that c-maf is a potent transactivator of
the IL-4 gene in vitro. The mechanism by which c-maf at-
tenuates the Th1 differentiation program is still unclear, but
clearly is Th2-cytokine independent. Taken together, this
study demonstrates that c-maf is a critical and pluripotent
transcription factor that promotes the differentiation of Th2
cells.
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